LOCATION

HOTEL SB DIAGONAL ZERO 4*SUP - BARCELONA
PL. DE LLEVANT, S/N, PLANTA -1, SANT MARTÍ,
08019 BARCELONA, SPAIN

CONFERENCE ORGANIZERS

GENE2CURE FOUNDATION

SPONSORS & PARTNERS (COMING MORE)

fundación columbus
VIRALGEN
GANDfoundation Small Genes, Big Stories
Children's Medical Research Institute
Jeans for Genes
Palčica Pomagalčica
PUS3 FOUNDATION
Czech Centre for Phenogenomics

SOCIAL MEDIA
@GENE2CURE

WEBSITE
WWW.GENE2CURE.COM

GENE2CURE FOUNDATION

GENE2CURE FOUNDATION TRANSLATIONAL GENE THERAPY CONFERENCE 2026

BARCELONA, JUNE 17 2026

PROGRAM

FROM RARE DISEASE TO CLINICAL DEVELOPMENT: BUILDING SCALABLE GENE THERAPY PROGRAMS

BARCELONA, SPAIN JUNE 16-17, 2026

JUNE 16, PRE-CONFERENCE MEETING

The Gene2Cure Translational Gene Therapy Conference brings together rare disease foundations, scientists, clinicians, and translational experts to accelerate gene therapy programs for ultra-rare neurodevelopmental disorders.

JUNE 16, PRE-CONFERENCE MEETING	
Closed working meetings for invited collaborators. Speakers and collaborators are invited to arrive on June 16 to participate in focused disease specific strategic sessions. These meetings are designed to define opportunities, technical challenges, and development priorities for each program.	
14:00 - 16:00	**PUS3 and GAND syndrome research strategy round table**
20:00	**Pre-conference dinner & networking reception** *Private dinner with speakers, collaborators and foundation leaders.*
END OF PRE-CONFERENCE MEETING	

JUNE 17, MAIN CONFERENCE DAY

The main conference day presents the research updates on the therapies Gene2Cure is developing. Sessions highlight scientific advances, preclinical development, regulatory preparation, followed by dedicated program sessions for GAND and PUS3 syndrome diseases.

8:30	**REGISTRATON AND NETWORKING COFFEE**
09:00	**Why Gene2Cure exist: Building beyond a single therapy** *Dr. Špela Miroševič, PhD (Co-founder or Gene2Cure Foundation)*
09:20	**How gene therapy works: From vector engineering to clinical delivery** *Dr. Leszek Lisowski, PhD (Co-founder of Gene2Cure Foundation)*
09:40	**Bridging the gene therapy cleft: Nonclinical safety assessment roadmap to clinical success** *Dr. Basel Assaf, PhD (Attentive Science Limited, USA)*
10:00	**Early preclinical development: from mouse models to therapeutic efficacy studies** *Dr. Jan Procházka, PhD (The Czech Centre for Phenogenomics)*
10:20	**Gene therapy of the brain and methods of its surgical delivery - personal experience** Dr. Miroslaw Zabek, PhD, MD (Gamma Knife Center, Poland)
11:00	**COFFEE BREAK AND NETWORKING**
11:20	**The role of Fiocruz in supporting rare diseases** *Dr. Antonio C. Campos de Carvalho, MD, PhD*
11:40	**PUS3 Foundation strategy and fundraising vision** *Jan Kieszczynski (PUS3 Foundation, Poland)*
12:00	**GAND Foundation: Our story, foundation strategy and fundraising vision** *Jernej Blatnik (GAND Foundation, Slovenia)*
12:15	**Disease biology and therapeutic targeting in PUS3 and GAND syndrome** *Prof. dr. Robert Smigiel (Medical University of Wroclaw, Poland)*
13:00	**LUNCH BREAK AND NETWORKING**
14:30	**Developing GATAD2B constructs and performing initial preclinical in vitro validation** *Dr. Florencia Haase, PhD (Children's Medical Research Institute, Australia)*
14:55	**Strategy in developing PUS3 constructs and initial in vitro validation** *Simone Borsani (Children's Medical Research Institute, CMRI, Australia)*
15:20	**PUS3 and GAND syndrome mouse model development and preparing for efficacy studies** *Dr. Duško Lainšček, PhD (Co-founder of Gene2Cure Foundation)*
15:45	**Round table with experts to discuss preclinical and clinical strategy for PUS3 and GAND syndrome**
16:30	**END OF GENE2CURE FOUNDATION CONFERENCE**